| MICHAEL-J-FOX-FOUNDATION |
MICHAEL-J-FOX-FOUNDATION |
92%
|
In fiscal year 2025, the Company received a grant of A$42 thousand from the sale of Paxalisib to the Michael J Fox Foundation to explore the therapeutic potential of Paxalisib as a treatment for Park… |
| BDO-AUDIT-PTY-LTD |
BDO-AUDIT-PTY-LTD |
85%
|
uation involved auditor judgment due to the nature and extent of audit effort required to address these matters, including the extent of specialized skill or knowledge needed. The primary procedures … |
| SOVARGEN-CO-LTD |
SOVARGEN-CO-LTD |
85%
|
or the years ended 30 June 2025, 2024, and 2023, no contract milestones were met, therefore no revenue was recognized. License Agreement with Sovargen Co Ltd. In March 2024, the Company entered into … |
| CUSTOMERS |
CUSTOMERS |
80%
|
Increases in manufacturing costs could adversely affect the Company’s future profitability if it was unable to pass all of the increased costs along to its customers. |
| CLRB |
Cellectar Biosciences, Inc. |
72%
|
pate will be required to complete clinical development of a product candidate or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend signif… |
| CLRB |
Cellectar Biosciences, Inc. |
72%
|
Reciprocal relationship from CLRB graph: Reciprocal relationship from KZIA graph: pate will be required to complete clinical development of a product candidate or if we experience significant delays … |
| PPCB |
Propanc Biopharma, Inc. |
72%
|
Reciprocal relationship from PPCB graph: novel expression system and are also in the process of optimizing conditions to achieve high titers of recombinant trypsinogen and chymotrypsinogen. Further, … |
| ANSARADA-GROUP-LIMITED |
ANSARADA-GROUP-LIMITED |
62%
|
pate will be required to complete clinical development of a product candidate or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend signif… |
| ANTARES-PHARMA-INC |
ANTARES-PHARMA-INC |
62%
|
pate will be required to complete clinical development of a product candidate or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend signif… |
| ANTX |
AN2 Therapeutics, Inc. |
62%
|
Reciprocal relationship from ANTX graph: Reciprocal relationship from KZIA graph: Reciprocal relationship from ANTX graph: Reciprocal relationship from KZIA graph: Reciprocal relationship from ANTX g… |
| CONTROLLER-ELISSA-HANSEN-COMPANY |
CONTROLLER-ELISSA-HANSEN-COMPANY |
62%
|
pate will be required to complete clinical development of a product candidate or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend signif… |
| GLIOBLAST-PTY-LTD |
GLIOBLAST-PTY-LTD |
62%
|
ry information about the parent entity. Parent 2024 A$’000 2023 A$’000 Statement of profit or loss and other comprehensive income Loss after income tax ( 24,008 ) ( 20,863 ) Total comprehensive loss … |
| GRANT-THORNTON-AUDIT-PTY-LTD |
GRANT-THORNTON-AUDIT-PTY-LTD |
62%
|
al reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. Our audit inclu… |
| HAEMALOGIX-PTY-LTD |
HAEMALOGIX-PTY-LTD |
62%
|
pate will be required to complete clinical development of a product candidate or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend signif… |
| KAZIA-LABORATORIES-PTY-LTD |
KAZIA-LABORATORIES-PTY-LTD |
62%
|
025 A$’000 2024 A$’000 Statement of profit or loss and other comprehensive income Loss after income tax ( 18,195 ) ( 24,008 ) Total comprehensive loss ( 18,195 ) ( 24,008 ) 2025 A$’000 2024 A$’000 St… |
| KAZIA-RESEARCH-PTY-LTD |
KAZIA-RESEARCH-PTY-LTD |
62%
|
025 A$’000 2024 A$’000 Statement of profit or loss and other comprehensive income Loss after income tax ( 18,195 ) ( 24,008 ) Total comprehensive loss ( 18,195 ) ( 24,008 ) 2025 A$’000 2024 A$’000 St… |
| KAZIA-THERAPEUTICS-INC |
KAZIA-THERAPEUTICS-INC |
62%
|
025 A$’000 2024 A$’000 Statement of profit or loss and other comprehensive income Loss after income tax ( 18,195 ) ( 24,008 ) Total comprehensive loss ( 18,195 ) ( 24,008 ) 2025 A$’000 2024 A$’000 St… |
| KILINWATA-INVESTMENTS-PTY-LTD |
KILINWATA-INVESTMENTS-PTY-LTD |
62%
|
Item 16K. Cybersecurity Cybersecurity Risk Management and Strategy We operate in the biotechnology sector, which is subject to various cybersecurity risks that could adversely affect our business, fi… |
| NASDAQ-STOCK-MARKET-LLC |
NASDAQ-STOCK-MARKET-LLC |
62%
|
costs could adversely affect the Company’s future profitability if it was unable to pass all of the increased costs along to its customers. The Company relies on third-party contract manufacturing or… |
| NOVOGEN-LIMITED |
NOVOGEN-LIMITED |
62%
|
Item 16K. Cybersecurity Cybersecurity Risk Management and Strategy We operate in the biotechnology sector, which is subject to various cybersecurity risks that could adversely affect our business, fi… |
| QBIOTICS-GROUP-LIMITED |
QBIOTICS-GROUP-LIMITED |
62%
|
pate will be required to complete clinical development of a product candidate or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend signif… |
| SIMCERE-PHARMACEUTICAL-GROUP |
SIMCERE-PHARMACEUTICAL-GROUP |
62%
|
ned useful life is the remaining life of the patent over the asset, unless other factors over-ride this assessment. Impairment of licensing agreements and other indefinite life intangible assets The … |
| SIMCERE-PHARMACEUTICAL-GROUP-LTD |
SIMCERE-PHARMACEUTICAL-GROUP-LTD |
62%
|
ned useful life is the remaining life of the patent over the asset, unless other factors over-ride this assessment. Impairment of licensing agreements and other indefinite life intangible assets The … |
| TRIAXIAL-PTY-LTD |
TRIAXIAL-PTY-LTD |
62%
|
Item 16K. Cybersecurity Cybersecurity Risk Management and Strategy We operate in the biotechnology sector, which is subject to various cybersecurity risks that could adversely affect our business, fi… |
